Condition: Diphtheria, Tetanus and Acellular Pertussis · Epidemic Meningitis · Haemophilus Influenzae Type B Infection · Sponsor: CanSino Biologics Inc.
This clinical trial is conducted in two parts. Part One employs a randomized, partially blinded, dose-escalation, partially active-controlled design. Part Two utilizes a randomized, blinded, placebo-controlled design. Part One is divided into four stages based on age and vaccine dose levels. Part Two consists of the 2-month-old vaccine/placebo groups.
This description comes directly from the study's public registry record.
Ying Wang · 022-58213600-6051 · ying.wang@cansinotech.com
Always discuss trial participation with your own doctor first.
| Liangyuan District Center for Disease Control and Prevention, Shangqiu City | Shangqiu, Henan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07203755